FDA 483 - fusion iv pharmaceuticals, inc. - March 23, 2017

An FDA inspection conducted from March 13 to March 23, 2017, at Fusion IV Pharmaceuticals, Inc., operating as Axle Pharmaceuticals, a producer of sterile drug products, identified significant compliance deficiencies. The inspection, guided by Current Good Manufacturing Practices (CGMP) and specific requirements for outsourcing facilities, revealed eight critical observations requiring corrective action. Key issues included a lack of robust procedures to prevent microbiological contamination, evidenced by uninvestigated media fill failures, absence of smoke pattern tests, and inadequate personnel practices in sterile areas. The firm also failed to adequately validate sterilization processes, with critical equipment qualifications exhibiting temperature deviations and incomplete incubation records for testing. Additionally, control over endotoxin and bioburden in container processing was not demonstrated, daily environmental monitoring was insufficient for certain production lots, and essential laboratory tests, such as method suitability for sterility and antibacterial effectiveness studies, were not completed. Labeling was found deficient, missing the required "Office use only" statement on multiple drug products, and labeling control was lax. Lastly, the facility failed to submit its initial report to the FDA identifying compounded products, as mandated for outsourcing facilities. Fusion IV Pharmaceuticals must thoroughly address these observations to ensure the safety, quality, and regulatory compliance of its sterile drug products.